Stockscreener 앱 받기
115.46
2.07%
-2.44
시간 외 거래:
115.71
0.25
+0.22%
전일 마감가:
$117.90
열려 있는:
$117.13
하루 거래량:
11.38M
Relative Volume:
1.01
시가총액:
$285.17B
수익:
$64.93B
순이익/손실:
$18.26B
주가수익비율:
15.87
EPS:
7.2751
순현금흐름:
$12.36B
1주 성능:
-5.89%
1개월 성능:
+0.03%
6개월 성능:
+37.58%
1년 성능:
+51.01%
1일 변동 폭
$114.71
$117.85
1주일 범위
$114.71
$123.01
52주 변동 폭
$73.31
$125.14
머크앤드컴퍼니 Stock (MRK) Company Profile
명칭
Merck Co Inc
전화
908-740-4000
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
115.46 | 291.20B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
903.99 | 808.52B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.54 | 574.86B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.99 | 368.65B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.47 | 312.04B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
149.73 | 290.19B | 54.72B | 14.02B | 15.32B | 7.1855 |
머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-02-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-08 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-10-13 | 재개 | Citigroup | Neutral |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-02-18 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-02-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-01-08 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-12-04 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-11 | 다운그레이드 | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-03-11 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2024-01-04 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-27 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Hold |
| 2023-04-13 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-03-28 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2023-03-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | 개시 | Jefferies | Buy |
| 2023-02-22 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-10-10 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-14 | 업그레이드 | Berenberg | Hold → Buy |
| 2022-07-06 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | 재개 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-16 | 개시 | Daiwa Securities | Neutral |
| 2021-12-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-12-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-29 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-01 | 업그레이드 | Argus | Hold → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-08-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-06-12 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-16 | 개시 | SVB Leerink | Outperform |
| 2019-07-03 | 개시 | Mizuho | Buy |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-05-13 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | 재확인 | Citigroup | Buy |
| 2018-10-09 | 재개 | Guggenheim | Buy |
| 2018-04-23 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-04-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-03-12 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-07 | 재확인 | Morgan Stanley | Equal-Weight |
| 2018-01-16 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
머크앤드컴퍼니 주식(MRK)의 최신 뉴스
Merck & Co. Inc. stock underperforms Thursday when compared to competitors - MarketWatch
FDA grants priority review to Merck-Daiichi’s B7-H3 cancer ADC - BioWorld News
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance UK
KBC Group NV Increases Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Lbp Am Sa Has $39.73 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Diversified Management Inc. Invests $909,000 in Merck & Co., Inc. $MRK - MarketBeat
Cwm LLC Buys 61,957 Shares of Merck & Co., Inc. $MRK - MarketBeat
Childress Capital Advisors LLC Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Farther Finance Advisors LLC Raises Holdings in Merck & Co., Inc. $MRK - MarketBeat
Adelphi Trust Co Acquires Shares of 10,969 Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
BCS Wealth Management Boosts Position in Merck & Co., Inc. $MRK - MarketBeat
Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug - MSN
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock sustained up - AD HOC NEWS
Merck & Co. Inc. stock (US58933Y1055): Is its oncology dominance strong enough to unlock new upside? - AD HOC NEWS
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside? - AD HOC NEWS
Is Merck & Co. (NYSE:MRK) Driving Growth In The Russell 1000 Index? - Kalkine Media
HARTFORD CAPITAL APPRECIATION HLS FUND's Merck & Co Inc(MRK) Holding History - GuruFocus
Merck & Co. Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside? - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Acquired by Norris Perne & French LLP MI - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Why Keytruda's dominance now matters more for investors? - AD HOC NEWS
Merck transforms itself through dealmaking as clock ticks on top-selling drug - Financial Times
Merck & Co., Inc. (NYSE:MRK) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's patent cliff the real test ahead? - AD HOC NEWS
Merck & Co. Inc. stock (US58933Y1055): Is Keytruda's dominance now the real test amid patent pressur - AD HOC NEWS
UBS Group Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price - MarketBeat
Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance now the real test for sustained grow - AD HOC NEWS
U.S. Capital Wealth Advisors LLC Has $6.56 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Burney Co. - MarketBeat
MRK Stock Price, Quote & Chart | MERCK & CO. INC. (NYSE:MRK) - ChartMill
Sumitomo Mitsui Trust Group Inc. Has $733.85 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Robeco Institutional Asset Management B.V. Has $262.94 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Massachusetts Financial Services Co. MA Sells 3,132,999 Shares of Merck & Co., Inc. $MRK - MarketBeat
Ritholtz Wealth Management Purchases 10,305 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Choreo LLC - MarketBeat
Carnegie Investment Counsel Grows Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Prime Capital Investment Advisors LLC Sells 20,072 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Position Lessened by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat
Bartlett & CO. Wealth Management LLC Has $13.24 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Bar Harbor Wealth Management Has $18.11 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock: Key drivers powering long-term pharma growth - AD HOC NEWS
Merck & Co., Inc. $MRK Shares Purchased by Roffman Miller Associates Inc. PA - MarketBeat
Top 12 Pharma Companies: Eli Lilly Shoots To The Top, Merck Tumbles - Citeline News & Insights
Cardinal Capital Management Inc. Has $32.06 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Douglas Lane & Associates LLC Has $59.56 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Merck Beats 295 Zostavax Suits Over Missed Deadlines - Law360
Merck & Co., Inc. stock: Undervalued by 39% despite strong gains? - AD HOC NEWS
Merck & Co.'s Quarterly Earnings Preview: What You Need to Know - Barchart.com
OFI Invest Asset Management Sells 27,934 Shares of Merck & Co., Inc. $MRK - MarketBeat
Newman Dignan & Sheerar Inc. Trims Stake in Merck & Co., Inc. $MRK - MarketBeat
머크앤드컴퍼니 (MRK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.55%
0.27%
자본화:
|
볼륨(24시간):